COX17

Across TCGA pan-cancer cohorts, COX17 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated COX17 data layer compared with 26 for mass-spec protein.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher COX17 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated COX17 expression acts as an unfavorable survival marker, although some lineages such as LUAD and OV show a favorable association.

HNSC, CCRCC, and LUAD are the cancer types where COX17 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	DFS	Median	II,III,IV	0.899	0.989	.004	13	view →
CCRCC	DFS	Median	All	0.537	0.922	.006	9	view →
LUAD	OS	Median	III,IV	0.670	0.219	.007	9	view →
OV	DFS	Median	All	1.000	0.871	.048	4	view →
UCEC	OS	Tertile	III,IV	1.000	0.427	.039	4	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

COX17–HNSC (DFS)

Open the HNSC breakdown →